Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | HCAR2 | Q8TDS4 | 10/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14340938 | 0.88 | HCAR2 (0.68) | HCAR2CYP2C8CYP2C9 | |
| SCHEMBL14340939 | 0.77 | L3MBTL1 (0.58) | CYP2C9 | |
| SCHEMBL6014493 | 0.76 | NAMPT (0.63) | KDM4EMAPTSMN1; SMN2TSHRMAPK10 | |
| SCHEMBL15295184 | 0.74 | KDM6B (0.72) | KDM4EMAPTSMN1; SMN2TSHRMAPK10 | |
| SCHEMBL2822906 | 0.73 | ALDH1A1 (0.53) | SMN1; SMN2TSHRHSD17B10 | |
| SCHEMBL553848 | 0.72 | ALDH1A1 (0.60) | SMN1; SMN2TSHR | |
| SCHEMBL14466725 | 0.72 | L3MBTL1 (0.71) | CYP2C9 | |
| SCHEMBL7108471 | 0.72 | KDM4E (1.00) | KDM4EHCAR2SMN1; SMN2TSHRMAPK10 | |
| SCHEMBL4861758 | 0.71 | SMN1; SMN2 (0.72) | KDM4ESMN1; SMN2TSHRMAPK10HSD17B10 | |
| SCHEMBL7632830 | 0.70 | KDM4E (0.72) | KDM4ESMN1; SMN2TSHRMAPK10HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-06 | — | — | US | disclosed |
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | GPR119, FFAR1, HCAR1 | KDM4E 4753/4885HCAR2 7/4885MAPT 2674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.